Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPT vs SAPT Following LAAC (NAPT-LAAC)
NCT07125417Phase 4Recruiting
- Sponsor
- OCEAN-SHD Study Group
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in Atrial fibrillation (AFib) (2 arms), sponsored by OCEAN-SHD Study Group. Primary endpoint: Composite of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding at 4 years. Started May 2025; status: recruiting.
02
Drugs
aspirin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07125417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125417.